Information on concomitant therapy is not routinely requested during the primary stage of monitoring because this is time consuming for practitioners and compliance with completing the questionnaires would fall. Should this information be required at a secondary stage during the evaluation of a problem, it is requested then (Beggs et al., 1999). However, when it is clear that knowledge of concomitant therapy is going to be essential, it is requested on the primary questionnaires, e.g. corticosteroid use with montelukast and anti-ulcer therapy with the COX-2 inhibitors.
Was this article helpful?